Document is current
Any future updates will be listed below
-
Authors
Payne, N. Connor https://orcid.org/0000-0001-9513-6194
Kalyakina, Alena S. https://orcid.org/0000-0003-1685-8151
Singh, Kritika https://orcid.org/0000-0001-5168-9176
Tye, Mark A. https://orcid.org/0000-0002-9456-0767
Mazitschek, Ralph https://orcid.org/0000-0002-1105-689X
-
Funding
Funding for this research was provided by:
National Science Foundation (DGE1745303, NSF 1830941)
Karlsruher Institut für Technologie
U.S. Department of Health & Human Services | National Institutes of Health (R01AI143723, R21AI13298, R01AI143723)
- License Information
-
More Information
Article History
Received: 24 February 2021
Accepted: 11 August 2021
First Online: 21 October 2021
Competing interests
: R.M. is a scientific advisory board (SAB) member and equity holder of Regenacy Pharmaceuticals, ERX Pharmaceuticals and Frequency Therapeutics. R.M., N.C.P. and A.S.K. are inventors on patent applications related to this work.
